| This article has been viewed: 2055times Download 1137次 |
 Scan with your phone! |
| 基于UPLC-Q-TOF-MS的泽兰体内外化学成分解析及其抗卵巢癌的网络药理学机制研究 |
| 焦柱铖1,包永睿1,2,3,王帅1,2,3,李天娇1,2,3,孟宪生1,2,3 |
|
|
| (1.辽宁中医药大学药学院,辽宁 大连 116600;2.辽宁省中药多维分析专业技术创新中心,辽宁 大连 116600;3.辽宁省现代中药研究工程实验室,辽宁 大连 116600) |
|
| 摘要: |
| 目的 系统分析泽兰化学成分及入血成分,为阐明泽兰抗卵巢癌药效物质基础提供理论依据。方法 运用超高效液相色谱-四极杆飞行时间串联质谱(UPLC-Q-TOF-MS)技术,结合文献、数据库以及二级碎片离子信息,对泽兰提取物、空白血浆及含药血浆成分进行表征及鉴定;利用SwissTargetsPrediction、GeneCards数据库检索筛选泽兰入血成分抗卵巢癌作用靶点,明确泽兰抗卵巢癌药效物质基础,最后通过不同浓度泽兰提取物干预SKOV-3卵巢癌细胞,评价泽兰对SKOV-3卵巢癌细胞活力影响。结果 通过比较相同检测条件下泽兰提取物、空白血浆、含药血浆,从泽兰提取物中初步鉴定了49个化合物,包括黄酮类、萜类、酚类等;从泽兰含药血浆中鉴定表征了12个入血成分。基于此,通过网络药理学挖掘泽兰抗卵巢癌关键靶点10个,且泽兰提取液可呈剂量依赖性促进SKOV-3卵巢癌细胞凋亡。结论 系统分析鉴定了泽兰提取物及其入血化学成分,发现泽兰入血成分可能是其发挥抗卵巢癌作用的药效成分,进一步明确了泽兰抗卵巢癌药效物质基础。 |
| 关键词: 泽兰 入血成分 卵巢癌 SKOV-3细胞 超高效液相色谱-四极杆飞行时间串联质谱 网络药理学 |
| DOI:10.13506/j.cnki.jpr.2026.04.004 |
| 基金项目: |
|
Received Date:October 09, 2025
Revision Date:April 01, 2006
Publication Date:April 30, 2026
|
|
| Investigation of the chemical components of Lycopus lucidus in vitro and in vivo based on UPLC-Q-TOF-MS and the network pharmacology mechanism against ovarian cancer |
| JIAO Zhucheng1,BAO Yongrui1,2,3,WANG Shuai1,2,3,LI Tianjiao1,2,3,MENG Xiansheng1,2,3 |
| (1.College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600,China;1.College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600,China; 2.Liaoning Provincial Technical Innovation Center for Multidimensional Analysis of Traditional Chinese Medicine, Dalian 116600,China; 3. Modern Chinese Medicine Research Engineering Laboratory of Liaoning Province, Dalian 116600,China) |
| Abstract: |
| Objective To systematically analyze the chemical components of Lycopus lucidus and its blood-absorbed components, thereby providing a theoretical basis for elucidating the pharmacodynamic material basis of its anti-ovarian cancer effects. Methods UPLC-Q-TOF-MS was employed to characterize and identify components in the Lycopus lucidus extract, blank plasma, and drug-containing plasma, by consulting literature and databases and analyzing secondary fragment ions. The SwissTargetPrediction and GeneCards databases were used to retrieve and screen the targets of the blood-absorbed components against ovarian cancer, aiming to clarify the pharmacodynamic material basis. Finally, SKOV-3 ovarian cancer cells were treated with different concentrations of the extract to evaluate its impact on cell viability. Results By comparing the extract, blank plasma, and drug-containing plasma under identical analytical conditions, 49 compounds were preliminarily identified from the Lycopus lucidus extract, including flavonoids, terpenoids, and phenolics. Among these, 12 components were characterized as blood-absorbed constituents. Based on this, network pharmacology identified 10 key targets related to the anti-ovarian cancer activity of Lycopus lucidus. Furthermore, the Lycopus lucidus extract promoted SKOV-3 cell apoptosis in a dose-dependent manner.Conclusion This study systematically identified the chemical components of the Lycopus lucidus extract and its blood-absorbed constituents. The results indicate that the blood-absorbed components are likely the effective substances responsible for its anti-ovarian cancer effects, further clarifying the pharmacodynamic material basis of Lycopus lucidus against ovarian cancer. |
| Key words: Lycopus lucidus Turcz. var. hirtus Regel Blood-absorbed components SKOV-3 Network pharmacology |